Publication details
1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens
| Authors | |
|---|---|
| Year of publication | 2012 |
| Type | Article in Periodical |
| Magazine / Source | Leukemia & lymphoma |
| MU Faculty or unit | |
| Citation | |
| Web | http://informahealthcare.com/doi/abs/10.3109/10428194.2012.684349 |
| Doi | http://dx.doi.org/10.3109/10428194.2012.684349 |
| Field | Oncology and hematology |
| Keywords | In-Situ Hybridization; Expression; Chromosome-1; Survival; Model |
| Attached files | |
| Description | In this study we assessed the prognostic value of amp(1q21) alone and in combination with del(17p13), del(13q14) and t(4,14)(p16;q32) detected by fl uorescence in situ hybridization(FISH) in newly diagnosed patients with MM treated with thalidomide-based induction regimens. Th e primary endpoints were response rate after fi rst-line therapy, PFS and OS. |